vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and National Storage Affiliates Trust (NSA). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $187.0M, roughly 1.3× National Storage Affiliates Trust). National Storage Affiliates Trust runs the higher net margin — 12.2% vs 11.1%, a 1.1% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -1.6%). National Storage Affiliates Trust produced more free cash flow last quarter ($299.8M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -2.4%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
National Storage Affiliates Trust is a U.S.-headquartered real estate investment trust focused on self-storage assets. It owns, operates and acquires self-storage facilities across dozens of U.S. states, offering secure storage solutions for residential and commercial customers.
ANIP vs NSA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $187.0M |
| Net Profit | $27.5M | $22.9M |
| Gross Margin | — | 72.5% |
| Operating Margin | 14.1% | 20.2% |
| Net Margin | 11.1% | 12.2% |
| Revenue YoY | 29.6% | -1.6% |
| Net Profit YoY | 367.5% | 36.8% |
| EPS (diluted) | $1.14 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $187.0M | ||
| Q3 25 | $227.8M | $188.7M | ||
| Q2 25 | $211.4M | $188.8M | ||
| Q1 25 | $197.1M | $188.4M | ||
| Q4 24 | $190.6M | $190.1M | ||
| Q3 24 | $148.3M | $193.6M | ||
| Q2 24 | $138.0M | $190.4M | ||
| Q1 24 | $137.4M | $196.1M |
| Q4 25 | $27.5M | $22.9M | ||
| Q3 25 | $26.6M | $18.4M | ||
| Q2 25 | $8.5M | $19.5M | ||
| Q1 25 | $15.7M | $13.0M | ||
| Q4 24 | $-10.3M | $16.7M | ||
| Q3 24 | $-24.2M | $18.7M | ||
| Q2 24 | $-2.3M | $17.1M | ||
| Q1 24 | $18.2M | $59.0M |
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 70.7% | ||
| Q2 25 | — | 70.5% | ||
| Q1 25 | — | 70.7% | ||
| Q4 24 | — | 72.5% | ||
| Q3 24 | — | 72.8% | ||
| Q2 24 | — | 72.6% | ||
| Q1 24 | — | 72.1% |
| Q4 25 | 14.1% | 20.2% | ||
| Q3 25 | 15.9% | 15.8% | ||
| Q2 25 | 6.6% | 16.5% | ||
| Q1 25 | 13.3% | 11.0% | ||
| Q4 24 | -2.3% | 14.5% | ||
| Q3 24 | -13.8% | 15.8% | ||
| Q2 24 | 3.7% | 17.2% | ||
| Q1 24 | 14.8% | 48.9% |
| Q4 25 | 11.1% | 12.2% | ||
| Q3 25 | 11.7% | 9.8% | ||
| Q2 25 | 4.0% | 10.3% | ||
| Q1 25 | 8.0% | 6.9% | ||
| Q4 24 | -5.4% | 8.8% | ||
| Q3 24 | -16.3% | 9.7% | ||
| Q2 24 | -1.7% | 9.0% | ||
| Q1 24 | 13.2% | 30.1% |
| Q4 25 | $1.14 | $0.23 | ||
| Q3 25 | $1.13 | $0.17 | ||
| Q2 25 | $0.36 | $0.19 | ||
| Q1 25 | $0.69 | $0.10 | ||
| Q4 24 | $-0.45 | $0.19 | ||
| Q3 24 | $-1.27 | $0.18 | ||
| Q2 24 | $-0.14 | $0.16 | ||
| Q1 24 | $0.82 | $0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $23.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $946.0M |
| Total Assets | $1.4B | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $23.3M | ||
| Q3 25 | $262.6M | $26.3M | ||
| Q2 25 | $217.8M | $26.1M | ||
| Q1 25 | $149.8M | $19.3M | ||
| Q4 24 | $144.9M | $50.4M | ||
| Q3 24 | $145.0M | $69.9M | ||
| Q2 24 | $240.1M | $59.0M | ||
| Q1 24 | $228.6M | $64.2M |
| Q4 25 | $540.7M | $946.0M | ||
| Q3 25 | $505.8M | $973.1M | ||
| Q2 25 | $436.8M | $1.0B | ||
| Q1 25 | $418.6M | $1.0B | ||
| Q4 24 | $403.7M | $1.1B | ||
| Q3 24 | $405.9M | $986.9M | ||
| Q2 24 | $455.8M | $1.2B | ||
| Q1 24 | $452.0M | $1.3B |
| Q4 25 | $1.4B | $5.1B | ||
| Q3 25 | $1.4B | $5.1B | ||
| Q2 25 | $1.3B | $5.2B | ||
| Q1 25 | $1.3B | $5.3B | ||
| Q4 24 | $1.3B | $5.4B | ||
| Q3 24 | $1.3B | $5.4B | ||
| Q2 24 | $920.8M | $5.3B | ||
| Q1 24 | $914.5M | $5.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $338.5M |
| Free Cash FlowOCF − Capex | $29.1M | $299.8M |
| FCF MarginFCF / Revenue | 11.8% | 160.3% |
| Capex IntensityCapex / Revenue | 0.5% | 20.7% |
| Cash ConversionOCF / Net Profit | 1.10× | 14.79× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $541.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $338.5M | ||
| Q3 25 | $44.1M | $100.2M | ||
| Q2 25 | $75.8M | $79.9M | ||
| Q1 25 | $35.0M | $85.6M | ||
| Q4 24 | $15.9M | $363.1M | ||
| Q3 24 | $12.5M | $105.7M | ||
| Q2 24 | $17.4M | $83.2M | ||
| Q1 24 | $18.3M | $94.0M |
| Q4 25 | $29.1M | $299.8M | ||
| Q3 25 | $38.0M | $88.0M | ||
| Q2 25 | $71.8M | $73.8M | ||
| Q1 25 | $32.5M | $79.9M | ||
| Q4 24 | $13.5M | $344.4M | ||
| Q3 24 | $7.7M | $101.8M | ||
| Q2 24 | $13.0M | $79.5M | ||
| Q1 24 | $13.7M | $88.6M |
| Q4 25 | 11.8% | 160.3% | ||
| Q3 25 | 16.7% | 46.6% | ||
| Q2 25 | 34.0% | 39.1% | ||
| Q1 25 | 16.5% | 42.4% | ||
| Q4 24 | 7.1% | 181.2% | ||
| Q3 24 | 5.2% | 52.6% | ||
| Q2 24 | 9.4% | 41.7% | ||
| Q1 24 | 10.0% | 45.2% |
| Q4 25 | 0.5% | 20.7% | ||
| Q3 25 | 2.7% | 6.5% | ||
| Q2 25 | 1.9% | 3.2% | ||
| Q1 25 | 1.3% | 3.0% | ||
| Q4 24 | 1.3% | 9.8% | ||
| Q3 24 | 3.2% | 2.0% | ||
| Q2 24 | 3.2% | 1.9% | ||
| Q1 24 | 3.3% | 2.7% |
| Q4 25 | 1.10× | 14.79× | ||
| Q3 25 | 1.66× | 5.44× | ||
| Q2 25 | 8.87× | 4.10× | ||
| Q1 25 | 2.23× | 6.59× | ||
| Q4 24 | — | 21.70× | ||
| Q3 24 | — | 5.65× | ||
| Q2 24 | — | 4.88× | ||
| Q1 24 | 1.00× | 1.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
NSA
Segment breakdown not available.
